213 related articles for article (PubMed ID: 33217537)
41. Oxidation pathway and exacerbations in COPD: the role of NAC.
Matera MG; Calzetta L; Cazzola M
Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
[TBL] [Abstract][Full Text] [Related]
42. Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents.
Poole PJ; Black PN
Am J Respir Med; 2003; 2(5):367-70. PubMed ID: 14719989
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of erdosteine in the treatment of chronic rhinosinusitis with nasal polyposis - a pilot study.
Hoza J; Salzman R; Starek I; Schalek P; Kellnerova R
Rhinology; 2013 Dec; 51(4):323-7. PubMed ID: 24260764
[TBL] [Abstract][Full Text] [Related]
44. N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses.
Papi A; Alfano F; Bigoni T; Mancini L; Mawass A; Baraldi F; Aljama C; Contoli M; Miravitlles M
Arch Bronconeumol; 2024 May; 60(5):269-278. PubMed ID: 38555190
[TBL] [Abstract][Full Text] [Related]
45. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
Tse HN; Tseng CZ
Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
[TBL] [Abstract][Full Text] [Related]
46. N-acetylcysteine in patients with COPD exacerbations associated with increased sputum.
Ayfer Aytemur Z; Baysak A; Ozdemir O; Köse T; Sayiner A
Wien Klin Wochenschr; 2015 Apr; 127(7-8):256-61. PubMed ID: 25595117
[TBL] [Abstract][Full Text] [Related]
47. Pemphigus herpetiformis-type drug reaction caused by erdosteine containing mucolytic in a child.
Akoglu G; Yavuz SO
Cutan Ocul Toxicol; 2017 Sep; 36(3):302-304. PubMed ID: 27881029
[TBL] [Abstract][Full Text] [Related]
48. Effectiveness of erdosteine, a second generation mucolytic agent, in children with acute rhinosinusitis: a randomized, placebo controlled, double-blinded clinical study.
Unuvar E; Tamay Z; Yildiz I; Toprak S; Kilic A; Aydin S; Kilic G; Guler N; Oguz F; Sidal M
Acta Paediatr; 2010 Apr; 99(4):585-9. PubMed ID: 20055782
[TBL] [Abstract][Full Text] [Related]
49. Carbocisteine for acute exacerbations of COPD.
Waller P; Suissa S
Lancet; 2008 Nov; 372(9650):1630; author reply 1631-2. PubMed ID: 18994655
[No Abstract] [Full Text] [Related]
50. Erdosteine reduces the exercise-induced oxidative stress in patients with severe COPD: Results of a placebo-controlled trial.
Dal Negro RW; Visconti M
Pulm Pharmacol Ther; 2016 Dec; 41():48-51. PubMed ID: 27651323
[TBL] [Abstract][Full Text] [Related]
51. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
Poole PJ; Black PN
Cochrane Database Syst Rev; 2000; (2):CD001287. PubMed ID: 10796634
[TBL] [Abstract][Full Text] [Related]
52. Antioxidants and mucolytics in COPD management: when (if ever) and in whom?
Hillas G; Nikolakopoulou S; Hussain S; Vassilakopoulos T
Curr Drug Targets; 2013 Feb; 14(2):225-34. PubMed ID: 23256719
[TBL] [Abstract][Full Text] [Related]
53. A PEACE-ful solution to COPD exacerbations?
Albert P; Calverley P
Lancet; 2008 Jun; 371(9629):1975-6. PubMed ID: 18555897
[No Abstract] [Full Text] [Related]
54. Carbocisteine for acute exacerbations of COPD.
Mohapatra PR; Aggarwal D
Lancet; 2008 Nov; 372(9650):1630-1; author reply 1631-2. PubMed ID: 18994656
[No Abstract] [Full Text] [Related]
55. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.
Cazzola M; Calzetta L; Facciolo F; Rogliani P; Matera MG
Respir Res; 2017 Jan; 18(1):26. PubMed ID: 28118826
[TBL] [Abstract][Full Text] [Related]
56. Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis.
Olivieri D; Del Donno M; Casalini A; D'Ippolito R; Fregnan GB
Respiration; 1991; 58(2):91-4. PubMed ID: 1862257
[TBL] [Abstract][Full Text] [Related]
57. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
van Overveld FJ; Demkow U; Górecka D; de Backer WA; Zielinski J
J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787
[TBL] [Abstract][Full Text] [Related]
58. New Perspectives for Mucolytic, Anti-inflammatory and Adjunctive Therapy with 1,8-Cineole in COPD and Asthma: Review on the New Therapeutic Approach.
Juergens LJ; Worth H; Juergens UR
Adv Ther; 2020 May; 37(5):1737-1753. PubMed ID: 32200535
[TBL] [Abstract][Full Text] [Related]
59. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
Poole PJ; Black PN
Cochrane Database Syst Rev; 2003; (2):CD001287. PubMed ID: 12804402
[TBL] [Abstract][Full Text] [Related]
60. Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats.
Fadillioğlu E; Erdoğan H; Söğüt S; Kuku I
J Appl Toxicol; 2003; 23(1):71-4. PubMed ID: 12518339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
